CA2106073C - Composition for promoting tissue repair and regeneration - Google Patents
Composition for promoting tissue repair and regeneration Download PDFInfo
- Publication number
- CA2106073C CA2106073C CA002106073A CA2106073A CA2106073C CA 2106073 C CA2106073 C CA 2106073C CA 002106073 A CA002106073 A CA 002106073A CA 2106073 A CA2106073 A CA 2106073A CA 2106073 C CA2106073 C CA 2106073C
- Authority
- CA
- Canada
- Prior art keywords
- pdgf
- tissue
- composition
- dexamethasone
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Disclosed is a method for the regeneration of tissue, the treatment of external wounds and the treatment of periodontal dis-ease comprising applying to the affected tissue an effective amount of a composition comprised of platelet-derived growth factor (PDGF) and an anti-inflammatory compound. The presence of the anti-inflammatory compound potentiates the activity of PDGF in stimulating cell growth, thereby enhancing tissue regeneration and/or wound healing.
Description
WO 92/16181 ~ ~ ~ ~ ~ ~ ~ PGT/US92/02043 METHOD FOR PROMOTING
TISSUE REPAIR AND REGENERATION
Background of the Invention Polypeptide growth factors are a class of natural biological mediators that regulate the proliferation, differentiation, motility and matrix synthesis of nearly all cell types. These properties, demonstrable in vivo, have led to the proposal that such factors play important roles in soft and hard tissue repair.
Platelet-derived growth factor (PDGF) is a well characterized example of such a polypeptide growth factor.
PDGF is a peptide hormone produced by blood platelets which influences the regulation of a broad array of biological systems including wound repair, arteriosclerosis, neoplasia, embryogenesis and bone marrow fibrosis. PDGF is a mitogen, that is, a substance which induces mitosis of cells and thus cellular proliferation. In wound repair, PDGF elicits both chemotactic and mitogenic responses in fibroblasts, smooth muscle, glial cells, etc. Injury to the endothelium lining the vessel wall is believed to cause platelets to adhere to exposed connective tissue at the wound site, with the concomitant release of PDGF. The released PDGF is thought to chemotactically recruit many cell types including fibroblasts, monocytes, glial and smooth muscle to migrate into the site of the wound. Increased proliferation of these cells leads to accelerated tissue regeneration and wound healing.
It has been demonstrated that the mitogenic properties of PDGF can be augmented by the addition of growth factors. For example, Antonaides et al. in U.S.
Patent Nos. 4,861,757 and 4,874,746 showed that a ~~flfla'~3 combination of PDGF and insulin-like growth factor-1 (IGF-1) or transforming growth factor alpha (TGF-a) had a greater effect on cell mitogenic activity than PDGF
alone.
The effect of combining PDGF with other compounds is less clear. Levenson et al. in J. Biol. Chem.,.
260:8056-63 (1985), showed that the synthetic glucocorticoid, dexamethasone, acts synergistically with cartilage-derived growth factor (CDGF) to enhance the stimulation of DNA synthesis in quiescent Swiss 3T3 cells, while having only a neutral effect with PDGF.
In addition, Levenson et al. showed that the addition of dexamethasone to PDGF-stimulated cultures had no effect on DNA synthesis over that observed with PDGF
alone.
.... _3_ ~~~~
Summary of the Invention The present invention relates to a method for enhancing tissue regeneration and/or wound repair in a mammal comprising applying to the tissue or wound an effective amount of a composition comprising an anti-inflammatory compound and PDGF. The method promotes cellular activity at the site of the wound which expedites healing of the wound.
More specifically, the combination of PDGF and anti-inflammatory compound synergistically promotes the proliferation of mammalian cells at the site. Either natural-sourced or recombinant PDGF can be used in the composition. It has been found that many anti-inflammatory agents can synergistically enhance the mitogenic effect of PDGF on cells. Anti-inflammatory agents which are particularly useful are a class of compounds known as glucocorticoids. Glucocorticoids include cortisone, hydrocortisone (cortisol), dexamethasone, and pharmacologically active derivatives thereof, for example.
The method of the present invention can be used to promote tissue regeneration and/or wound healing in a variety of tissues. The method is effective for enhancing tissue regeneration and wound healing in epithelial tissues, and for promoting regeneration of bone and/or cartilage tissues. In general, applying the composition to an area where epithelium, bone or cartilage has been broken, torn or eroded due to injury or disease, for example, stimulates the regeneration and repair of the epithelium, bone or cartilage.
The method is particularly effective for treating tissues affected by periodontal disease. The method is carried out by applying a composition of PDGF and the anti-inflammatory compound to the affected gum tissue and periodontal ligament. The composition promotes ?.1~~~~3 regeneration of the gum tissue, of tooth tissues such as dentin and pulp, and of the connective tissue holding the tooth in place in the gum.
The present method provides an effective therapeutic composition for treating external wounds, including skin ulcers, burns and lesions and for regenerating connective tissue and/or bone. The method is particularly effective for treating dental tissue affected by periodontal disease.
_. j _ Brief Description o.f the Draw~nas Figure 1 is a gra~>h showing the influence of dexametha.sone on the mitogenic activity of both PDGF ,clone and PDGF + IGF-1.
Figure 2 is a graph showing the effect on cell population density of various concentrations of dexamethasone, includz.ng 0 M, 10-5 M, 10-~
M, 10-12 M, and l0~is M, wherein said dexamethasone is addec:i to PDGF + IGF-1.
Figure 3 is a gra~,~h showing the' i~~fluence of dexamethasone on the mitogenic activity of PDGF' using PDGF + IGF-1 a.s a control reference.
Figure 4 is a graph compariner the mitogenic activity of PDGF-as and PDGF-(i(3.
Detailed Description of the Invention The present method comprises applying a combination of PDGF and an anti-inflammatory compound to a tissue.
Native PDGF is a dimeric molecule comprised of two polypeptide chains, one or more of which may be glycosylated. The two chains (referred to as alpha (a), and beta (S)) are homologous but not identical. The a chain has a molecular weight of about 17,000 to 18,000 and the ~ chain has a molecular weight of about 13,000 to 14,000. The a and ~ chains are synthesized in vivo from larger molecules which are subsequently processed at the amino and carboxyl-termini. The mature human a chain is comprised of 110 or 125 amino acids and various N-linked sugar side chains, and the length and amino acid sequence is dependent on the tissue source. The fully processed human ~ chain is encoded by the c-sis gene and is comprised of 112 amino acids. Biologically active PDGF
can exist as a homodimer e.g., aa, ~~, or a heterodiminer a~3. The molecular weights of the as homodimer and ~~ homodimer are about 35,000 and about 32,000, respectively.
PDGF useful in the present invention may be natural sourced, recombinant or synthetic PDGF. Natural sourced can be extracted from human platelets, for example as described by Heidin _et _a1. (1979) Proc.
Natl. Acad. Sci. USA, 76:3722-33726; Antoniades _et a1.(1979) Proc. Natl. Acad. Sci. USA, 76:1809-1813;
Antoniades et al., U.S. Patent No. 4,479,896; and Lipton et al., U.S. Patent No. 4,350,687. Recombinant PDGF can be produced using transformed eucaryotic cells, such as yeast, (See, EP Publication No.
0177957), or procaryotic cells such as _E. coli. PDGF
also can be synthesized using art-recognized peptide synthesis techniques. Biologically active fragments, W'O 92/16181 PCT/US92/02043 . -- -~-derivatives or mutant forms of PDGF can be used in the present invention. PDGF which can be used is commercially available, for example, from Amgen Corporation, Thousand Oaks, California; PDGF Inc., Boston, Massachusetts; Collaborative Research Inc., Waltham, Massachusetts; and Creative BioMolecules, Inc., Hopkinton, Massachusetts.
Anti-inflammatory compounds are compounds which reduce inflammation by acting on body mechanics without directly antagonizing the causative agent. A class of anti-inflammatory compounds which is particularly useful in the present method comprises glucocorticoids.
Glucocorticoids include, for example, cortisone, hydrocortisone (cortisol), dexamethasone and pharmacologically active derivatives of these drugs, e.g., hydrocortisone acetate. Dexamethasone and cortisol are commercially available from a number of sources, for example, Sigma Chemical Co., Saint Louis, Missouri.
Wound healing and tissue regeneration can be promoted by directly, locally applying an effective amount of a composition comprising PDGF and the selected anti-inflammatory compound to the affected tissue. The tissue can be external epithelial tissue, internal epithelial tissue, bone, cartilage, or dental tissue, including gum tissue, dentin, pulp, cementum or periodontal ligature.
The concentration of PDGF and of the anti-inflammatory compound will depend in part upon the compound selected, its potency and the tissue it is applied to. The amount can be determined empirically by applying a low dose and observing the effects and incrementally increasing the dose until the desired effect is obtained. A concentration of PDGF of from about 0.1 Ng/ml to about 10 mg/ml is effective for most w K~;,'c~ r'GT~ PTO i 1 JUN i~~3 _. - 8 - PCT/ US 92 ~ 0 20 4 2~oso~~ 3 applications. For many glucocorticoids, a concentration of from about 10-5 M to about 10-12 M can be used. For example, a concentration of from about 10-5 M to about 10-12M of dexamethasone has been shown to significantly enhance the activity to PDGF. A
composition containing from about 3.92 Ng/ml (10-SM) to about 0.000392 mg/ml (10-12M) of dexamethasone (which has a molecular weight of about 392 g/mole) is preferred for most applications. A concentration of about 10-5 to about 10-9M is most preferred.
Other growth factors such as transforming growth factor-a (TGF-a) and insulin-like growth factors (TGF-1) can be added to the composition containing PDGF
and the anti-inflammatory compound to further enhance healing or regeneration of injured tissue. TGF-a, IGF-1 or other growth factor can be added to the PDGF
mixture in a weight-to-weight ratio, for example, of about 1:4 and 25:1, preferably between about 1:2 and 10: I, and more preferably 1:1 or 2:1.
In a preferred embodiment of the present invention, the composition of PDGF and the anti-inflammatory compound is combined with a pharmaceutically acceptable carrier substance for local, topical administration.
Examples of pharmaceutically acceptable carriers include, for example, commercially available inert gels, or liquids supplemented with albumin, methyl cellulose or a collagen matrix. Typical of such formulations are ointments, creams and gels. Ointments are typically prepared using an oleaginous base, e.g., containing mixed oils or hydrocarbons, such as white petrolatum or mineral oil, or an absorbent base, e.g., consisting of an absorbent anhydrous substance or substances, for example, anhydrous lanolin. Following formation of the base, the active ingredients are added in the desired concentration. Creams generally SUBSTITUTE SHEET
IPEAIUS
16 Recd PCI~ P T4 1 1 ~ l~N 1993 . , - 9 - p(~T ~ ~1 s g~ ~
02- ~~
comprise an oil phase (internal phase) containing typically fixed oils, hydrocarbons, and the like, such as waxes, petrolatum, mineral oil, and the like, and an aqueous phase (continuous phase), comprising water and any water-soluble substances, such as added salts. The two phases are stabilized by use of an emulsifying agent, for example, a surface active agent, such as sodium lauryl sulfate; hydrophilic colloids, such as acacia colloidal clays, beegum, and the like. Upon formation of the emulsion, the active ingredients are added in the desired concentration. Gels are comprised of a base selected from an oleaginous base, water, or an emulsion-suspension base, as previously described.
To the base is added a gelling agent which forms a matrix in the base, increasing its viscosity to a semisolid consistency. Examples of gelling agents are hydroxypropyl cellulose, acrylic acid polymers, and the like. The active ingredients are added to the formulation at the desired concentration at a point preceding additior. of the gelling agent.
The amounts of PDGF and anti-inflammatory compound incorporated into the formulation of the present invention is not critical; the concentration should be sufficient to permit ready application of the formulation to the wound area in an amount which will deliver the desired amount of PDGF and the anti-inflammatory compound. A typical gel formulation useful for the topical administration of PDGF and dexamethasone, for example, comprises the following:
by weight sterile distilled water 92.38 sodium dibasic phosphate 0.03 CarbapolT" 0.5 glycerin 1.6 m-cresol 0.25 sodium hydroxide (1N) 0.5 ~UgSTiTUTE SHEr'~
~~EAIUS ~- . .
. ... -.: aN W v . ... . ..~w r. ....;.W~~.~
.. . N'0 92/16181 PCT/l'S92i0~0-!3 A bone collagen matrix as described in U.S. Patent No. 4,975,526 can be used as the carrier for application to bone and/or cartilage. The collagen matrix described in this patent is a biodegradable, biocompatible, mineral-free, insoluble Type-I bone collagen particles being depleted of non-collagenous protein. The collagen matrix particles have a mean diameter of about 70 arm - 850 arm, and an increased intraparticle surface area relative to untreated material. In this embodiment, PDGF and the anti-inflammatory agent are first dissolved in a suitable solvent such as buffered sterile saline and then added to the collagen matrix. The mixture is vortexed, and the matrix is lyophilized and shaped as desired or implanted into an area of bone or cartilage by packing.
Other useful matrix materials include synthetic homopolymers and copolymers of glycolic acid and lactic acid, hydroxyapatite, tricalcium and other calcium phosphates, and particulate demineralized guanidine extracted species-specific (allogenic) bone. The matrix containing the PDGF and steroid can be applied into a shape spanning the bone or cartilage defect to serve as a "temporary scaffold" and substratum as a base for anchoring and proliferation of differentiated tissue cells.
The method is particularly useful for treating tissues affected by periodontal disease. Periodontal disease is characterized by gingivitis, destruction of alveolar bone and periodontal ligament, apical migration of the epithelial attachment resulting in the formation of periodontal pockets. Thus, a number of different tissues are involved, including epithelium, cartilage and bone. The method of the invention ._a -11-promotes healing and regeneration of the gum tissues (epithial tissue) the periodontal ligament (cartilage) and the jaw bone (bone). Pulp and dentin tissue within the tooth which was eroded or attacked by periodontal disease can be regenerated using the present method.
The most preferred composition for this purpose is a combination of PDGF and dexamethasone.
The data shown in the following Examples all demonstrate that PDGF mitogenesis is enhanced in the presence of a glucocorticoid. Current methodologies described in the literature disclose the use of PDGF as an agent to enhance tissue repair or reduce regeneration in vivo utilizing another human growth factor, IGF-1 in combination with PDGF. This is substantially more expensive and less effective than using the small amounts (e.g., less than 10-5M) of glucocorticoid drugs, as described herein. In addition, the glucocorticoids have anti-inflammatory properties, which are beneficial where inflammation is present, such as with many periodontal diseases. As demonstrated herein, the addition of a glucocorticoid drug in a preferred concentration of from about 10-'M
to about 10-9M was consistently more effective than adding 1Ng/ml IFG-1 for enhancing the cell proliferation which is the basis of tissue regeneration and repair.
The invention will be more readily understood by the following specific non-limiting examples which are included for purposes of illustration.
R7C ~MT~T.R C
Example 1: Potentiation of mitogenic effect of PDGF
and IGF-1 by Dexamethasone The following experiments were all performed on low passage, human diploid fibroblasts obtained from the periodontal ligaments and dental pulps of extracted teeth. The cells were cultured under standard culture conditions and stocks were propagated with loo fetal bovine serum (FBS) as the source of growth factors.
For the experiments detailed here, the cells were plated at 10,000 to 15,000 cells per 1.88 cmz of surface area in 24 well culture plates and conditioned in medium containing O.le FBS for 24-48 hours prior to treatment. The cells were then exposed once to the indicated concentrations of PDGF, IGF-1 and/or dexamethasone in culture media at time zero. The cells were quantitatively harvested from each well and the total cell population densities were determined using a Coulter counter by standard methods. The PDGF-~~ and PDGF-as used in these studies were recombinant human analogs of PDGF produced in E. coli which were provided by Creative BioMolecules, Hopkinton, Massachusetts.
The dexamethasone was purchased from Sigma Chemical Company, St. Louis, Missouri.
Cell cultures in 24 well plates prepared as described above were treated with the following materials and the extent of cell growth determined.
Plate 1 contained O.lo FBS
Plate 2 contained 0.1% FBS
Plate 3 contained PDGF-~~ 200 ng/ml + 1GF-1 200 ng/ml Plate 4 contained PDGF-~~ 200 ng/ml + 1GF-1 200 ng/ml + 10-5M Dexamethasone Plate 5 contained PDGF-~~ 200 ng/ml + 1GF-1 200 ng/ml + 10 6M Dexamethasone Plate 6 contained PDGF-~~ 200 ng/ml + 1GF-1 200 ng/ml + 10-'M Dexamethasone Plate 7 contained PDGF-~~ 200 ng/ml + 1GF-1 200 M..~. -13-ng/ml + 10-9M Dexamethasone Plate 8 contained PDGF-~~ 200 ng/ml + 1GF-1 200 ng/ml + 10-1°M Dexamethasone Plate 9 contained PDGF-~~ 200 ng/ml + 1GF-1 200 ng/ml + 10-11M Dexamethasone Plate 10 contained PDGF-~~3 200 ng/ml + 1GF-1 200 ng/ml + 10~1zM Dexamethasone Plate 11 contained PDGF-~~ 200 ng/ml + 10-'M
Dexamethasone Plate 12 contained PDGF-~~ 200 ng/ml All of the plates except for plate 1 were incubated for 96 hours. Plate 1 was incubated for 30 minutes.
the cells then were removed from the plates and counted. The efficacy of the agents on cell mitogenic activity was measured by the number of cells per square centimeter after the incubation period.
The results are illustrated in Figures 1-2.
Figure 1 shows that cultures treated with dexamethasone in combination with PDGF proliferated faster than cultures treated with PDGF alone and PDGF + IGF-1.
Figure 2 shows that dexamethasone is effective in enhancing all proliferation over concentrations ranging from 10-5 to 10-11M. The concentration of dexamethasone to optimally potentiate the mitogenic activity of PDGF at 200 ng/ml is about 10-'M. The mitogenic activity of the cells was increased by the combination of dexamethasone and PDGF more than by just PDGF alone or PDGF + IGF-1. However, there was no further enhancement of mitogenic activities by the addition of IGF-1 to PDGF and dexamethasone.
Dexamethasone alone has no effect on cell mitogenic activity, as shown in Figure 4.
Example 2: Comparison of the effects on mitogenic activity of dexamethasone with IGF-1 over time.
To determine the time course of the effects of dexamethasone on PDGF-~3~3 mitogenic activity, cultures were treated with PDGF + IGF-1 and PDGF with and without dexamethasone at 10-' and 10-12M, harvested and counted at the time indicated over a period of 160 hours. Data from the same experiment are plotted against the controls in two separate plots for clarity.
The results, shown in Figure 3, revealed that a single exposure of the cultured cells at time zero to PDGF-~~ plus dexamethasone resulted in final increased cell population densities after 160 hours that were similar to those obtained by exposure of the cultured cells to PDGF-~~ plus IGF-1. The final total cell number was similar for treatment with 10 ng/ml and 500 ng/ml PDGF-~~. The PDGF-~~ + IGF-1 treated cultures reached maximal cell population densities at 96 hours, while those exposed to PDGF-~~ +
dexamethasone had not plateaued by 160 hours, demonstrating the prolonged effect of a single dose of PDGF + dexamethasone on cell proliferation.
Example 3: Comparison of the Mitogenic Activity of PDGF-as and PDGF-~~.
Plates prepared as described above were treated with PDGF-as or PDGF-~~ and dexamethasone or IGF-1.
The extent of cell growth determined.
PDGF-S~ Studies Plate 1 contained 0.1% FBS + 10-'M dexamethasone.
Plate 2 contained PDGF-~~ 500 ng/ml.
Plate 3 contained PDGF-~~ 500 ng/ml + IGF-1 500 ng/ml.
Plate 4 contained PDGF-SS 500 ng/ml + 10-5M
dexamethasone.
V~VO 92/16181 PCT/US92/02043 PDGF-as Studies Plate 5 contained 0.1~ FBS 10~' dexamethasone.
Plate 6 contained PDGF-as 500 ng/ml.
Plate 7 contained PDGF-as 500 ng/ml + IGF-1 500 ng/ml.
Plate 8 contained PDGF-as 500 ng/ml + 10-'M
dexamethasone.
The results of the present experiment, shown in Figure 4, which demonstrate that dexamethasone potentiates the mitogenic activity of both PDGF-as and PDGF-~3~. As shown in Figure 4, after a single application of PDGF plus dexamethasone, the rate of cell proliferation at 168 hours did not appear to have diminished. The data shown in Table 1 suggest that PDGF-~S is a more potent mitogen for these cells than PDGF-aa, and that PDGF-~~ treated cultures may be slightly more responsive to dexamethasone than PDGF-as treated cultures.
Ratios of Cell Population Densities PDGF-S~ DEX/PDGF-S~3 PDGF-as DEX + PDGF-as PDGF-~~ + PDGF-as 48 HOURS 1.24 0.92 1.08 96 HOURS 1.97 1.44 1.32 168 HOURS 2.73 2.19 1.57 Data are ratios of means of cells/cm2 from replicate experiments.
Equivalents One skilled in the art will be able to ascertain, with no more than routine experimentation, many equivalents to the specific embodiments described herein. Such equivalents are intended to be encompassed by the following claims.
TISSUE REPAIR AND REGENERATION
Background of the Invention Polypeptide growth factors are a class of natural biological mediators that regulate the proliferation, differentiation, motility and matrix synthesis of nearly all cell types. These properties, demonstrable in vivo, have led to the proposal that such factors play important roles in soft and hard tissue repair.
Platelet-derived growth factor (PDGF) is a well characterized example of such a polypeptide growth factor.
PDGF is a peptide hormone produced by blood platelets which influences the regulation of a broad array of biological systems including wound repair, arteriosclerosis, neoplasia, embryogenesis and bone marrow fibrosis. PDGF is a mitogen, that is, a substance which induces mitosis of cells and thus cellular proliferation. In wound repair, PDGF elicits both chemotactic and mitogenic responses in fibroblasts, smooth muscle, glial cells, etc. Injury to the endothelium lining the vessel wall is believed to cause platelets to adhere to exposed connective tissue at the wound site, with the concomitant release of PDGF. The released PDGF is thought to chemotactically recruit many cell types including fibroblasts, monocytes, glial and smooth muscle to migrate into the site of the wound. Increased proliferation of these cells leads to accelerated tissue regeneration and wound healing.
It has been demonstrated that the mitogenic properties of PDGF can be augmented by the addition of growth factors. For example, Antonaides et al. in U.S.
Patent Nos. 4,861,757 and 4,874,746 showed that a ~~flfla'~3 combination of PDGF and insulin-like growth factor-1 (IGF-1) or transforming growth factor alpha (TGF-a) had a greater effect on cell mitogenic activity than PDGF
alone.
The effect of combining PDGF with other compounds is less clear. Levenson et al. in J. Biol. Chem.,.
260:8056-63 (1985), showed that the synthetic glucocorticoid, dexamethasone, acts synergistically with cartilage-derived growth factor (CDGF) to enhance the stimulation of DNA synthesis in quiescent Swiss 3T3 cells, while having only a neutral effect with PDGF.
In addition, Levenson et al. showed that the addition of dexamethasone to PDGF-stimulated cultures had no effect on DNA synthesis over that observed with PDGF
alone.
.... _3_ ~~~~
Summary of the Invention The present invention relates to a method for enhancing tissue regeneration and/or wound repair in a mammal comprising applying to the tissue or wound an effective amount of a composition comprising an anti-inflammatory compound and PDGF. The method promotes cellular activity at the site of the wound which expedites healing of the wound.
More specifically, the combination of PDGF and anti-inflammatory compound synergistically promotes the proliferation of mammalian cells at the site. Either natural-sourced or recombinant PDGF can be used in the composition. It has been found that many anti-inflammatory agents can synergistically enhance the mitogenic effect of PDGF on cells. Anti-inflammatory agents which are particularly useful are a class of compounds known as glucocorticoids. Glucocorticoids include cortisone, hydrocortisone (cortisol), dexamethasone, and pharmacologically active derivatives thereof, for example.
The method of the present invention can be used to promote tissue regeneration and/or wound healing in a variety of tissues. The method is effective for enhancing tissue regeneration and wound healing in epithelial tissues, and for promoting regeneration of bone and/or cartilage tissues. In general, applying the composition to an area where epithelium, bone or cartilage has been broken, torn or eroded due to injury or disease, for example, stimulates the regeneration and repair of the epithelium, bone or cartilage.
The method is particularly effective for treating tissues affected by periodontal disease. The method is carried out by applying a composition of PDGF and the anti-inflammatory compound to the affected gum tissue and periodontal ligament. The composition promotes ?.1~~~~3 regeneration of the gum tissue, of tooth tissues such as dentin and pulp, and of the connective tissue holding the tooth in place in the gum.
The present method provides an effective therapeutic composition for treating external wounds, including skin ulcers, burns and lesions and for regenerating connective tissue and/or bone. The method is particularly effective for treating dental tissue affected by periodontal disease.
_. j _ Brief Description o.f the Draw~nas Figure 1 is a gra~>h showing the influence of dexametha.sone on the mitogenic activity of both PDGF ,clone and PDGF + IGF-1.
Figure 2 is a graph showing the effect on cell population density of various concentrations of dexamethasone, includz.ng 0 M, 10-5 M, 10-~
M, 10-12 M, and l0~is M, wherein said dexamethasone is addec:i to PDGF + IGF-1.
Figure 3 is a gra~,~h showing the' i~~fluence of dexamethasone on the mitogenic activity of PDGF' using PDGF + IGF-1 a.s a control reference.
Figure 4 is a graph compariner the mitogenic activity of PDGF-as and PDGF-(i(3.
Detailed Description of the Invention The present method comprises applying a combination of PDGF and an anti-inflammatory compound to a tissue.
Native PDGF is a dimeric molecule comprised of two polypeptide chains, one or more of which may be glycosylated. The two chains (referred to as alpha (a), and beta (S)) are homologous but not identical. The a chain has a molecular weight of about 17,000 to 18,000 and the ~ chain has a molecular weight of about 13,000 to 14,000. The a and ~ chains are synthesized in vivo from larger molecules which are subsequently processed at the amino and carboxyl-termini. The mature human a chain is comprised of 110 or 125 amino acids and various N-linked sugar side chains, and the length and amino acid sequence is dependent on the tissue source. The fully processed human ~ chain is encoded by the c-sis gene and is comprised of 112 amino acids. Biologically active PDGF
can exist as a homodimer e.g., aa, ~~, or a heterodiminer a~3. The molecular weights of the as homodimer and ~~ homodimer are about 35,000 and about 32,000, respectively.
PDGF useful in the present invention may be natural sourced, recombinant or synthetic PDGF. Natural sourced can be extracted from human platelets, for example as described by Heidin _et _a1. (1979) Proc.
Natl. Acad. Sci. USA, 76:3722-33726; Antoniades _et a1.(1979) Proc. Natl. Acad. Sci. USA, 76:1809-1813;
Antoniades et al., U.S. Patent No. 4,479,896; and Lipton et al., U.S. Patent No. 4,350,687. Recombinant PDGF can be produced using transformed eucaryotic cells, such as yeast, (See, EP Publication No.
0177957), or procaryotic cells such as _E. coli. PDGF
also can be synthesized using art-recognized peptide synthesis techniques. Biologically active fragments, W'O 92/16181 PCT/US92/02043 . -- -~-derivatives or mutant forms of PDGF can be used in the present invention. PDGF which can be used is commercially available, for example, from Amgen Corporation, Thousand Oaks, California; PDGF Inc., Boston, Massachusetts; Collaborative Research Inc., Waltham, Massachusetts; and Creative BioMolecules, Inc., Hopkinton, Massachusetts.
Anti-inflammatory compounds are compounds which reduce inflammation by acting on body mechanics without directly antagonizing the causative agent. A class of anti-inflammatory compounds which is particularly useful in the present method comprises glucocorticoids.
Glucocorticoids include, for example, cortisone, hydrocortisone (cortisol), dexamethasone and pharmacologically active derivatives of these drugs, e.g., hydrocortisone acetate. Dexamethasone and cortisol are commercially available from a number of sources, for example, Sigma Chemical Co., Saint Louis, Missouri.
Wound healing and tissue regeneration can be promoted by directly, locally applying an effective amount of a composition comprising PDGF and the selected anti-inflammatory compound to the affected tissue. The tissue can be external epithelial tissue, internal epithelial tissue, bone, cartilage, or dental tissue, including gum tissue, dentin, pulp, cementum or periodontal ligature.
The concentration of PDGF and of the anti-inflammatory compound will depend in part upon the compound selected, its potency and the tissue it is applied to. The amount can be determined empirically by applying a low dose and observing the effects and incrementally increasing the dose until the desired effect is obtained. A concentration of PDGF of from about 0.1 Ng/ml to about 10 mg/ml is effective for most w K~;,'c~ r'GT~ PTO i 1 JUN i~~3 _. - 8 - PCT/ US 92 ~ 0 20 4 2~oso~~ 3 applications. For many glucocorticoids, a concentration of from about 10-5 M to about 10-12 M can be used. For example, a concentration of from about 10-5 M to about 10-12M of dexamethasone has been shown to significantly enhance the activity to PDGF. A
composition containing from about 3.92 Ng/ml (10-SM) to about 0.000392 mg/ml (10-12M) of dexamethasone (which has a molecular weight of about 392 g/mole) is preferred for most applications. A concentration of about 10-5 to about 10-9M is most preferred.
Other growth factors such as transforming growth factor-a (TGF-a) and insulin-like growth factors (TGF-1) can be added to the composition containing PDGF
and the anti-inflammatory compound to further enhance healing or regeneration of injured tissue. TGF-a, IGF-1 or other growth factor can be added to the PDGF
mixture in a weight-to-weight ratio, for example, of about 1:4 and 25:1, preferably between about 1:2 and 10: I, and more preferably 1:1 or 2:1.
In a preferred embodiment of the present invention, the composition of PDGF and the anti-inflammatory compound is combined with a pharmaceutically acceptable carrier substance for local, topical administration.
Examples of pharmaceutically acceptable carriers include, for example, commercially available inert gels, or liquids supplemented with albumin, methyl cellulose or a collagen matrix. Typical of such formulations are ointments, creams and gels. Ointments are typically prepared using an oleaginous base, e.g., containing mixed oils or hydrocarbons, such as white petrolatum or mineral oil, or an absorbent base, e.g., consisting of an absorbent anhydrous substance or substances, for example, anhydrous lanolin. Following formation of the base, the active ingredients are added in the desired concentration. Creams generally SUBSTITUTE SHEET
IPEAIUS
16 Recd PCI~ P T4 1 1 ~ l~N 1993 . , - 9 - p(~T ~ ~1 s g~ ~
02- ~~
comprise an oil phase (internal phase) containing typically fixed oils, hydrocarbons, and the like, such as waxes, petrolatum, mineral oil, and the like, and an aqueous phase (continuous phase), comprising water and any water-soluble substances, such as added salts. The two phases are stabilized by use of an emulsifying agent, for example, a surface active agent, such as sodium lauryl sulfate; hydrophilic colloids, such as acacia colloidal clays, beegum, and the like. Upon formation of the emulsion, the active ingredients are added in the desired concentration. Gels are comprised of a base selected from an oleaginous base, water, or an emulsion-suspension base, as previously described.
To the base is added a gelling agent which forms a matrix in the base, increasing its viscosity to a semisolid consistency. Examples of gelling agents are hydroxypropyl cellulose, acrylic acid polymers, and the like. The active ingredients are added to the formulation at the desired concentration at a point preceding additior. of the gelling agent.
The amounts of PDGF and anti-inflammatory compound incorporated into the formulation of the present invention is not critical; the concentration should be sufficient to permit ready application of the formulation to the wound area in an amount which will deliver the desired amount of PDGF and the anti-inflammatory compound. A typical gel formulation useful for the topical administration of PDGF and dexamethasone, for example, comprises the following:
by weight sterile distilled water 92.38 sodium dibasic phosphate 0.03 CarbapolT" 0.5 glycerin 1.6 m-cresol 0.25 sodium hydroxide (1N) 0.5 ~UgSTiTUTE SHEr'~
~~EAIUS ~- . .
. ... -.: aN W v . ... . ..~w r. ....;.W~~.~
.. . N'0 92/16181 PCT/l'S92i0~0-!3 A bone collagen matrix as described in U.S. Patent No. 4,975,526 can be used as the carrier for application to bone and/or cartilage. The collagen matrix described in this patent is a biodegradable, biocompatible, mineral-free, insoluble Type-I bone collagen particles being depleted of non-collagenous protein. The collagen matrix particles have a mean diameter of about 70 arm - 850 arm, and an increased intraparticle surface area relative to untreated material. In this embodiment, PDGF and the anti-inflammatory agent are first dissolved in a suitable solvent such as buffered sterile saline and then added to the collagen matrix. The mixture is vortexed, and the matrix is lyophilized and shaped as desired or implanted into an area of bone or cartilage by packing.
Other useful matrix materials include synthetic homopolymers and copolymers of glycolic acid and lactic acid, hydroxyapatite, tricalcium and other calcium phosphates, and particulate demineralized guanidine extracted species-specific (allogenic) bone. The matrix containing the PDGF and steroid can be applied into a shape spanning the bone or cartilage defect to serve as a "temporary scaffold" and substratum as a base for anchoring and proliferation of differentiated tissue cells.
The method is particularly useful for treating tissues affected by periodontal disease. Periodontal disease is characterized by gingivitis, destruction of alveolar bone and periodontal ligament, apical migration of the epithelial attachment resulting in the formation of periodontal pockets. Thus, a number of different tissues are involved, including epithelium, cartilage and bone. The method of the invention ._a -11-promotes healing and regeneration of the gum tissues (epithial tissue) the periodontal ligament (cartilage) and the jaw bone (bone). Pulp and dentin tissue within the tooth which was eroded or attacked by periodontal disease can be regenerated using the present method.
The most preferred composition for this purpose is a combination of PDGF and dexamethasone.
The data shown in the following Examples all demonstrate that PDGF mitogenesis is enhanced in the presence of a glucocorticoid. Current methodologies described in the literature disclose the use of PDGF as an agent to enhance tissue repair or reduce regeneration in vivo utilizing another human growth factor, IGF-1 in combination with PDGF. This is substantially more expensive and less effective than using the small amounts (e.g., less than 10-5M) of glucocorticoid drugs, as described herein. In addition, the glucocorticoids have anti-inflammatory properties, which are beneficial where inflammation is present, such as with many periodontal diseases. As demonstrated herein, the addition of a glucocorticoid drug in a preferred concentration of from about 10-'M
to about 10-9M was consistently more effective than adding 1Ng/ml IFG-1 for enhancing the cell proliferation which is the basis of tissue regeneration and repair.
The invention will be more readily understood by the following specific non-limiting examples which are included for purposes of illustration.
R7C ~MT~T.R C
Example 1: Potentiation of mitogenic effect of PDGF
and IGF-1 by Dexamethasone The following experiments were all performed on low passage, human diploid fibroblasts obtained from the periodontal ligaments and dental pulps of extracted teeth. The cells were cultured under standard culture conditions and stocks were propagated with loo fetal bovine serum (FBS) as the source of growth factors.
For the experiments detailed here, the cells were plated at 10,000 to 15,000 cells per 1.88 cmz of surface area in 24 well culture plates and conditioned in medium containing O.le FBS for 24-48 hours prior to treatment. The cells were then exposed once to the indicated concentrations of PDGF, IGF-1 and/or dexamethasone in culture media at time zero. The cells were quantitatively harvested from each well and the total cell population densities were determined using a Coulter counter by standard methods. The PDGF-~~ and PDGF-as used in these studies were recombinant human analogs of PDGF produced in E. coli which were provided by Creative BioMolecules, Hopkinton, Massachusetts.
The dexamethasone was purchased from Sigma Chemical Company, St. Louis, Missouri.
Cell cultures in 24 well plates prepared as described above were treated with the following materials and the extent of cell growth determined.
Plate 1 contained O.lo FBS
Plate 2 contained 0.1% FBS
Plate 3 contained PDGF-~~ 200 ng/ml + 1GF-1 200 ng/ml Plate 4 contained PDGF-~~ 200 ng/ml + 1GF-1 200 ng/ml + 10-5M Dexamethasone Plate 5 contained PDGF-~~ 200 ng/ml + 1GF-1 200 ng/ml + 10 6M Dexamethasone Plate 6 contained PDGF-~~ 200 ng/ml + 1GF-1 200 ng/ml + 10-'M Dexamethasone Plate 7 contained PDGF-~~ 200 ng/ml + 1GF-1 200 M..~. -13-ng/ml + 10-9M Dexamethasone Plate 8 contained PDGF-~~ 200 ng/ml + 1GF-1 200 ng/ml + 10-1°M Dexamethasone Plate 9 contained PDGF-~~ 200 ng/ml + 1GF-1 200 ng/ml + 10-11M Dexamethasone Plate 10 contained PDGF-~~3 200 ng/ml + 1GF-1 200 ng/ml + 10~1zM Dexamethasone Plate 11 contained PDGF-~~ 200 ng/ml + 10-'M
Dexamethasone Plate 12 contained PDGF-~~ 200 ng/ml All of the plates except for plate 1 were incubated for 96 hours. Plate 1 was incubated for 30 minutes.
the cells then were removed from the plates and counted. The efficacy of the agents on cell mitogenic activity was measured by the number of cells per square centimeter after the incubation period.
The results are illustrated in Figures 1-2.
Figure 1 shows that cultures treated with dexamethasone in combination with PDGF proliferated faster than cultures treated with PDGF alone and PDGF + IGF-1.
Figure 2 shows that dexamethasone is effective in enhancing all proliferation over concentrations ranging from 10-5 to 10-11M. The concentration of dexamethasone to optimally potentiate the mitogenic activity of PDGF at 200 ng/ml is about 10-'M. The mitogenic activity of the cells was increased by the combination of dexamethasone and PDGF more than by just PDGF alone or PDGF + IGF-1. However, there was no further enhancement of mitogenic activities by the addition of IGF-1 to PDGF and dexamethasone.
Dexamethasone alone has no effect on cell mitogenic activity, as shown in Figure 4.
Example 2: Comparison of the effects on mitogenic activity of dexamethasone with IGF-1 over time.
To determine the time course of the effects of dexamethasone on PDGF-~3~3 mitogenic activity, cultures were treated with PDGF + IGF-1 and PDGF with and without dexamethasone at 10-' and 10-12M, harvested and counted at the time indicated over a period of 160 hours. Data from the same experiment are plotted against the controls in two separate plots for clarity.
The results, shown in Figure 3, revealed that a single exposure of the cultured cells at time zero to PDGF-~~ plus dexamethasone resulted in final increased cell population densities after 160 hours that were similar to those obtained by exposure of the cultured cells to PDGF-~~ plus IGF-1. The final total cell number was similar for treatment with 10 ng/ml and 500 ng/ml PDGF-~~. The PDGF-~~ + IGF-1 treated cultures reached maximal cell population densities at 96 hours, while those exposed to PDGF-~~ +
dexamethasone had not plateaued by 160 hours, demonstrating the prolonged effect of a single dose of PDGF + dexamethasone on cell proliferation.
Example 3: Comparison of the Mitogenic Activity of PDGF-as and PDGF-~~.
Plates prepared as described above were treated with PDGF-as or PDGF-~~ and dexamethasone or IGF-1.
The extent of cell growth determined.
PDGF-S~ Studies Plate 1 contained 0.1% FBS + 10-'M dexamethasone.
Plate 2 contained PDGF-~~ 500 ng/ml.
Plate 3 contained PDGF-~~ 500 ng/ml + IGF-1 500 ng/ml.
Plate 4 contained PDGF-SS 500 ng/ml + 10-5M
dexamethasone.
V~VO 92/16181 PCT/US92/02043 PDGF-as Studies Plate 5 contained 0.1~ FBS 10~' dexamethasone.
Plate 6 contained PDGF-as 500 ng/ml.
Plate 7 contained PDGF-as 500 ng/ml + IGF-1 500 ng/ml.
Plate 8 contained PDGF-as 500 ng/ml + 10-'M
dexamethasone.
The results of the present experiment, shown in Figure 4, which demonstrate that dexamethasone potentiates the mitogenic activity of both PDGF-as and PDGF-~3~. As shown in Figure 4, after a single application of PDGF plus dexamethasone, the rate of cell proliferation at 168 hours did not appear to have diminished. The data shown in Table 1 suggest that PDGF-~S is a more potent mitogen for these cells than PDGF-aa, and that PDGF-~~ treated cultures may be slightly more responsive to dexamethasone than PDGF-as treated cultures.
Ratios of Cell Population Densities PDGF-S~ DEX/PDGF-S~3 PDGF-as DEX + PDGF-as PDGF-~~ + PDGF-as 48 HOURS 1.24 0.92 1.08 96 HOURS 1.97 1.44 1.32 168 HOURS 2.73 2.19 1.57 Data are ratios of means of cells/cm2 from replicate experiments.
Equivalents One skilled in the art will be able to ascertain, with no more than routine experimentation, many equivalents to the specific embodiments described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (27)
1. Use of a composition comprising a therapeutically effective amount of platelet-derived growth factor (PDGF) and a glucocorticoid for the manufacture of a medicament for promoting regeneration or repair of a tissue in a mammal.
2. Use according to claim 1, wherein the tissue is selected from the group consisting of:
epithelium, bone, cartilage and dental tissue.
epithelium, bone, cartilage and dental tissue.
3. Use according to claim 2, wherein the dental tissue is selected from the group consisting of: gum, periodontal ligament, bone, pulp and dentin tissue.
4. Use according to claim 1, wherein the glucacorticoid is selected from the group consisting: dexamethasone, cortisone and hydrocortisone.
5. Use according to claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.
6. Use of a composition comprising PDGF in a concentration of 0.1 µg/ml to 10 mg/ml and a glucocorticoid in a concentration of 10 -5 M to 10 -12 M for the manufacture of a medicament for promoting regeneration or repair of a tissue in a mammal.
7. Use according to claim 6, wherein the tissue is selected from the group consisting of:
epithelium, bone, cartilage and dental tissue.
epithelium, bone, cartilage and dental tissue.
8. Use according to claim 7, wherein the dental tissue is selected from the group consisting of: gum, periodontal ligament, bone, pulp and dentin tissue.
9. Use according to claim 6, wherein the glucocorticoid is selected from the group consisting of: dexamethasone, cortisone and hydrocortisone.
10. Use according to claim 6, wherein the composition further comprises a pharmaceutically acceptable carrier.
11. Use of a composition comprising PDGF in a concentration of 0.1 Ng/ml to 10 mg/ml and dexamethasone in a concentration of 10-5 M to 10 -12 M for the manufacture of a medicament for promoting regeneration or repair of a tissue in a mammal.
12. Use according to claim 11, wherein the tissue is selected from the group consisting of:
epithelium, bone, cartilage and dental tissue.
epithelium, bone, cartilage and dental tissue.
13. Use according to claim 12, wherein the dental tissue is selected from the group consisting of: gum, periodontal ligament, bone, pulp and dentin tissue.
14. Use according to claim 11, wherein the composition further comprises a pharmaceutically acceptable carrier.
15. A medicament composition for promoting regeneration or repair of a tissue in a mammal comprising PDGF in a concentration of 0.1 µg/ml to 10 mg/ml and a glucocorticoid in a concentration of 10 -5 M to 10 -12 M.
16. The composition of claim 15, wherein the tissue is selected from the group consisting of:
epithelium, bone, cartilage and dental tissue.
epithelium, bone, cartilage and dental tissue.
17. The composition of claim 16, wherein the dental tissue is selected from the group consisting of: gum, periodontal ligament, bone, pulp and dentin tissue.
18. The composition of claim 15, wherein the glucocorticoid is selected from the group consisting of: dexamethasone, cortisone and hydrocortisone.
19. The composition of claim 15, wherein the composition further comprises a growth factor in a growth factor: PDGF ratio of from about 1:4 to about 25:1.
20. The composition of claim 19, wherein the growth factor is selected from the group consisting of transforming growth factor-.alpha. and insulin-like growth factors.
21. The composition of claim 15, wherein the composition further comprises a pharmaceutically acceptable carrier.
22. A medicament composition for promoting regeneration or repair of a tissue in a mammal comprising PDGF in a concentration of 0.1 µg/ml to 10 mg/ml and dexamethasone in a concentration of 10 -5 M to 10 -12M.
23. The composition of claim 22, wherein the tissue is selected from the group consisting of epithelium, bone, cartilage and dental tissue.
24. The composition of claim 23, wherein the dental tissue is selected from the group consisting of: gum, periodontal ligament, bone, pulp and dentin tissue.
25. The composition of claim 22, wherein the composition further comprises a growth factor in a growth factor: PDGF ratio of from about 1:4 to about 25:1.
26. The composition of claim 25, wherein the growth factor is selected from the group consisting of transforming growth factor-.alpha. and insulin-like growth factors.
27. The composition of claim 22, wherein the composition further comprises a pharmaceutically acceptable carrier.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/669,070 US5149691A (en) | 1991-03-12 | 1991-03-12 | Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone |
| US669,070 | 1991-03-12 | ||
| PCT/US1992/002043 WO1992016181A2 (en) | 1991-03-12 | 1992-03-12 | Composition for promoting tissue repair and regeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2106073A1 CA2106073A1 (en) | 1993-09-13 |
| CA2106073C true CA2106073C (en) | 2003-09-30 |
Family
ID=24684879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002106073A Expired - Fee Related CA2106073C (en) | 1991-03-12 | 1992-03-12 | Composition for promoting tissue repair and regeneration |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US5149691A (en) |
| EP (1) | EP0575484B1 (en) |
| JP (1) | JPH07505858A (en) |
| AT (1) | ATE196604T1 (en) |
| AU (1) | AU656372B2 (en) |
| CA (1) | CA2106073C (en) |
| DE (1) | DE69231486T2 (en) |
| WO (1) | WO1992016181A2 (en) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5149691A (en) * | 1991-03-12 | 1992-09-22 | Creative Biomolecules, Inc. | Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone |
| US5770209A (en) * | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
| US5837258A (en) | 1991-08-30 | 1998-11-17 | University Of South Florida | Induction of tissue, bone or cartilage formation using connective tissue growth factor |
| US7384634B2 (en) * | 1991-08-30 | 2008-06-10 | University Of South Florida | Connective tissue growth factor |
| US5408040A (en) * | 1991-08-30 | 1995-04-18 | University Of South Florida | Connective tissue growth factor(CTGF) |
| US5444151A (en) * | 1992-05-15 | 1995-08-22 | Ludwig Institute For Cancer Research | Platelet derived growth factor antagonists |
| US5326695A (en) * | 1992-05-15 | 1994-07-05 | Ludwig Institute For Cancer Research | Platelet derived growth factor agonists |
| DE4228457A1 (en) * | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Production of heterodimeric PDGF-AB using a bicistronic vector system in mammalian cells |
| US5455041A (en) * | 1993-09-13 | 1995-10-03 | Research Foundation Of State University Of New York At Buffalo | Method for inducing periodontal tissue regeneration |
| US5942496A (en) * | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
| US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
| EP0743066A3 (en) * | 1995-05-16 | 1998-09-30 | Mitsui Pharmaceuticals, Inc. | Wound-healing agent |
| US6902584B2 (en) | 1995-10-16 | 2005-06-07 | Depuy Spine, Inc. | Bone grafting matrix |
| US5776193A (en) | 1995-10-16 | 1998-07-07 | Orquest, Inc. | Bone grafting matrix |
| US5885829A (en) * | 1996-05-28 | 1999-03-23 | The Regents Of The University Of Michigan | Engineering oral tissues |
| DE19754140A1 (en) * | 1997-12-05 | 1999-06-24 | Era Beschichtung Gmbh & Co Kg | Interior material based on plastic, process for its production and use |
| WO1999066797A1 (en) | 1998-06-22 | 1999-12-29 | Worden Charles E | Enriched platelet wound healant |
| AU1430601A (en) * | 1999-11-02 | 2001-05-14 | Eli Lilly And Company | Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders |
| US7847087B2 (en) | 2001-03-05 | 2010-12-07 | Siemens Healthcare Diagnostics Inc. | Methods and primers for evaluating HIV-1 mutations |
| EP1531837A4 (en) * | 2001-06-07 | 2006-11-15 | Chiou Consulting Inc | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions |
| US7819888B2 (en) * | 2001-10-23 | 2010-10-26 | Innovasive Devices, Inc. | Method and apparatus for harvesting and implanting bone plugs |
| DE10152956A1 (en) * | 2001-10-26 | 2003-05-15 | Fresenius Kabi De Gmbh | A pharmaceutical composition comprising a growth factor and / or a cytokine and an antiseptic biguanide |
| EP1507543A4 (en) | 2002-05-09 | 2006-07-26 | Cambridgemed Inc | A pharmaceutical composition for treatment of wounds containing blood plasma or serum |
| US20040018220A1 (en) * | 2002-07-26 | 2004-01-29 | Chiou Consulting, Inc. | Aqueous compositions for facial cosmetics |
| US6616923B1 (en) * | 2002-07-26 | 2003-09-09 | Chiou Consulting, Inc. | Aqueous compositions for facial cosmetics |
| ATE510605T1 (en) | 2003-03-14 | 2011-06-15 | Univ Columbia | SYSTEMS AND METHODS FOR BLOOD BASED THERAPY USING A MEMBRANELESS MICROFLUID EXCHANGE DEVICE |
| US20060076295A1 (en) | 2004-03-15 | 2006-04-13 | The Trustees Of Columbia University In The City Of New York | Systems and methods of blood-based therapies having a microfluidic membraneless exchange device |
| US7309232B2 (en) * | 2003-10-10 | 2007-12-18 | Dentigenix Inc. | Methods for treating dental conditions using tissue scaffolds |
| US7258875B2 (en) * | 2003-12-04 | 2007-08-21 | Chiou Consulting, Inc. | Compositions and methods for topical treatment of skin infection |
| US8293890B2 (en) * | 2004-04-30 | 2012-10-23 | Advanced Cardiovascular Systems, Inc. | Hyaluronic acid based copolymers |
| GB0414803D0 (en) * | 2004-07-01 | 2004-08-04 | Glaxo Group Ltd | Composition |
| US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
| US20060115266A1 (en) * | 2004-12-01 | 2006-06-01 | Gil Levi | All-optical protection signaling systems and methods in optical communication networks |
| WO2007016620A2 (en) | 2005-08-01 | 2007-02-08 | Genera Doo | Methods and compositions for regenerating articular cartilage |
| KR20080084808A (en) | 2005-11-17 | 2008-09-19 | 바이오미메틱 세라퓨틱스, 인크. | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
| EP1976864B1 (en) | 2006-01-23 | 2012-09-26 | Imagene Co., Ltd. | Novel peptide and use thereof |
| EP2311505B1 (en) * | 2006-02-09 | 2013-11-06 | BioMimetic Therapeutics, LLC | Compositions and methods for treating bone |
| CN101534917A (en) | 2006-05-22 | 2009-09-16 | 纽约市哥伦比亚大学理事会 | Systems and methods of microfluidic membraneless exchange using filtration of extraction fluid outlet streams |
| AU2007269712B2 (en) | 2006-06-30 | 2013-02-07 | Biomimetic Therapeutics, Llc | PDGF-biomatrix compositions and methods for treating rotator cuff injuries |
| US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| AU2013203287B2 (en) * | 2006-11-03 | 2015-12-17 | Biomimetic Therapeutics, Llc. | Compositions and methods for arthrodetic procedures |
| EP2462895B1 (en) | 2006-11-03 | 2016-11-02 | BioMimetic Therapeutics, LLC | Compositions and methods for arthrodetic procedures |
| US9511076B2 (en) * | 2008-05-30 | 2016-12-06 | Clarion Research Group | Formulations and methods for recovery from dental surgery |
| US8282963B2 (en) * | 2007-10-15 | 2012-10-09 | The Regents Of The University Of Colorado, A Body Corporate | Methods for extracting platelets and compositions obtained therefrom |
| ES2543254T3 (en) | 2008-01-07 | 2015-08-17 | Rapid Pathogen Screening, Inc. | Use of peptides to stimulate wound healing |
| MX2010008591A (en) | 2008-02-04 | 2010-08-30 | Univ Columbia | Fluid separation devices, systems and methods. |
| CN102014977B (en) | 2008-02-07 | 2015-09-02 | 生物模拟治疗有限责任公司 | For compositions and the method for Distraction Osteogenesis |
| MX2011002555A (en) | 2008-09-09 | 2011-08-03 | Biomimetic Therapeutics Inc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries. |
| EP2403508B1 (en) * | 2009-03-06 | 2015-10-28 | Université Paris Descartes | Method of treating cancer employing gingival fibroblast conditioned medium |
| AU2011217784B2 (en) | 2010-02-22 | 2014-10-09 | Biomimetic Therapeutics, Llc. | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
| JP2013536158A (en) | 2010-06-14 | 2013-09-19 | ジーン シグナル インターナショナル ソシエテ アノニム | Novel peptides for wound healing |
| EP2395015B1 (en) | 2010-06-14 | 2013-03-06 | Gene Signal International SA | Peptides for wound healing |
| US8288334B2 (en) | 2010-06-14 | 2012-10-16 | Gene Signal International Sa | Peptides for wound healing |
| EP2593126B1 (en) | 2010-07-12 | 2017-09-20 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases |
| US20130108683A1 (en) * | 2011-10-25 | 2013-05-02 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating partial and full thickness wounds and injuries |
| KR20140123571A (en) | 2012-02-16 | 2014-10-22 | 에이티와이알 파마, 인코포레이티드 | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
| JP6397479B2 (en) | 2013-03-15 | 2018-09-26 | エータイアー ファーマ， インコーポレイテッド | Histidyl-tRNA synthetase Fc conjugate |
| MX2017004520A (en) | 2014-10-14 | 2018-03-15 | Lynch Samuel | Compositions for treating wounds. |
| US11767520B2 (en) | 2017-04-20 | 2023-09-26 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
| KR20200060997A (en) | 2018-11-23 | 2020-06-02 | (주)메디코스바이오텍 | Pharmaceutical Composition for Treatment of Wounds |
| CZ308845B6 (en) | 2019-01-21 | 2021-07-07 | Globetech Innovation S.R.O | Pharmaceutical composition of topically healing peptide components for use in the topical treatment of skin defects and / or for topical wound healing |
| PL433169A1 (en) | 2020-03-06 | 2021-09-13 | Gdański Uniwersytet Medyczny | Lipopeptide conjugates and their salts, method for the preparation thereof, pharmaceutical composition containing a lipopeptide conjugate and its salts for the treatment of chronic wounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6028999A (en) * | 1983-06-30 | 1985-02-14 | Maruho Kk | Protein having cell proliferation accelerating action, its composition and its preparation |
| US4957742A (en) * | 1984-11-29 | 1990-09-18 | Regents Of The University Of Minnesota | Method for promoting hair growth |
| CA1322714C (en) * | 1986-11-14 | 1993-10-05 | Harry N. Antoniades | Wound healing and bone regeneration |
| US5124316A (en) * | 1986-11-14 | 1992-06-23 | President And Fellows Of Harvard College | Method for periodontal regeneration |
| JPH01501707A (en) * | 1986-12-11 | 1989-06-15 | ブリティッシュ・テクノロジー・グループ・リミテッド | Improvements in or relating to the use of epidermal growth factors |
| US4808402A (en) * | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
| US4874746A (en) * | 1987-12-22 | 1989-10-17 | Institute Of Molecular Biology, Inc. | Wound headling composition of TGF-alpha and PDGF |
| AU657472B2 (en) * | 1990-03-06 | 1995-03-16 | Claude Paul Genero | Towel or blanket support device |
| US5149691A (en) * | 1991-03-12 | 1992-09-22 | Creative Biomolecules, Inc. | Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone |
| JPH06506939A (en) * | 1991-04-12 | 1994-08-04 | クリエイティブ バイオモレキュルズ インコーポレイテッド | Treatment method for gastrointestinal ulcers using platelet-derived growth factors |
-
1991
- 1991-03-12 US US07/669,070 patent/US5149691A/en not_active Expired - Fee Related
-
1992
- 1992-03-12 AT AT92908042T patent/ATE196604T1/en not_active IP Right Cessation
- 1992-03-12 WO PCT/US1992/002043 patent/WO1992016181A2/en active IP Right Grant
- 1992-03-12 EP EP92908042A patent/EP0575484B1/en not_active Expired - Lifetime
- 1992-03-12 AU AU15591/92A patent/AU656372B2/en not_active Ceased
- 1992-03-12 CA CA002106073A patent/CA2106073C/en not_active Expired - Fee Related
- 1992-03-12 US US07/849,931 patent/US5376636A/en not_active Expired - Fee Related
- 1992-03-12 DE DE69231486T patent/DE69231486T2/en not_active Expired - Fee Related
- 1992-03-12 JP JP4507585A patent/JPH07505858A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69231486T2 (en) | 2001-04-26 |
| ATE196604T1 (en) | 2000-10-15 |
| EP0575484B1 (en) | 2000-09-27 |
| EP0575484A1 (en) | 1993-12-29 |
| CA2106073A1 (en) | 1993-09-13 |
| WO1992016181A2 (en) | 1992-10-01 |
| AU1559192A (en) | 1992-10-21 |
| WO1992016181A3 (en) | 1992-11-12 |
| US5376636A (en) | 1994-12-27 |
| US5149691A (en) | 1992-09-22 |
| JPH07505858A (en) | 1995-06-29 |
| AU656372B2 (en) | 1995-02-02 |
| DE69231486D1 (en) | 2000-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2106073C (en) | Composition for promoting tissue repair and regeneration | |
| Saito et al. | Bone‐resorbing activity and prostaglandin E produced by human periodontal ligament cells in vitro | |
| Oates et al. | Mitogenic effects of growth factors on human periodontal ligament cells in vitro | |
| GLOBUS et al. | Regulation of bovine bone cell proliferation by fibroblast growth factor and transforming growth factorβ | |
| CA2105997A1 (en) | Method of inhibiting padgem-mediated interactions using an inhibitor comprising a 2,6 sialic acid component | |
| US6287606B1 (en) | Methods of enhancing wound healing and tissue repair | |
| EP0679097B1 (en) | Tgf-beta formulation for inducing bone growth | |
| Beck et al. | In vivo induction of bone by recombinant human transforming growth factor β1 | |
| EP0455422A2 (en) | Method of treating or preventing baldness with compositions containing fibroblast growth factor | |
| JPH01121300A (en) | Polypeptide growth factor occurring from milk | |
| RU2140282C1 (en) | Composition stimulating growth of osteoblasts and containing and vitamin d | |
| JP2001506635A (en) | Compositions and methods for stimulating bone growth | |
| MX2007004459A (en) | Platelet-derived growth factor compositions and methods of use thereof. | |
| Gamal et al. | The effect of local delivery of PDGF‐BB on attachment of human periodontal ligament fibroblasts to periodontitis‐affected root surfaces–in vitro | |
| JP3395904B2 (en) | Methods for enhancing wound healing and tissue repair | |
| US6174541B1 (en) | Skin aging and wound treatment using cell migration agents | |
| AU621368B2 (en) | Pharmaceutical composition containing deoxyribonucleosides and/or deoxyribonucleotides for wound healing | |
| EP0531425B1 (en) | Combination of IGF-I and TGF-beta for bone regeneration | |
| Dubertret et al. | Activities of human acidic fibroblast growth factor in an in vitro dermal equivalent model | |
| Lowe et al. | Effects of leukemia inhibitory factor on bone resorption and DNA synthesis in neonatal mouse calvaria | |
| EP1498135B1 (en) | Dental viscous pharmaceutical containing basic fibroblast growth factor | |
| US7807628B2 (en) | Therapeutic agent for dentin-pulp complex regeneration | |
| JPH07504160A (en) | bone regeneration | |
| Mailhot et al. | Porous Polysulfone Coated With Platelet‐Derived Growth Factor‐BB Stimulates Proliferation of Human Periodontal Ligament Fibroblasts | |
| JPH07316066A (en) | Wound healing agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |